Circulating Tumor DNA (ctDNA)-based Minimal Residual Disease in Non-small Cell Lung Cancer

Overview

Journal Chin Med J Pulm Crit Care Med

Date 2024 Aug 22

PMID 39171282

Authors

Libo Tang

Ruiyang Li

Huahai Wen

Qing Zhou

Chongrui Xu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related fatalities, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancers. Over the past forty years, patients with NSCLC have had a 5-year survival rate of only 16%, despite improvements in chemotherapy, targeted therapy, and immunotherapy. Circulating tumor DNA (ctDNA) in blood can be used to identify minimal residual disease (MRD), and ctDNA-based MRD has been shown to be of significance in prognostic assessment, recurrence monitoring, risk of recurrence assessment, efficacy monitoring, and therapeutic intervention decisions in NSCLC. The level of MRD can be obtained by monitoring ctDNA to provide guidance for more precise and personalized treatment, the scientific feasibility of which could dramatically modify lung cancer treatment paradigm. In this review, we present a comprehensive review of MRD studies in NSCLC and focus on the application of ctDNA-based MRD in different stages of NSCLC in current clinical practice.

Citing Articles

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era.

Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C Int J Mol Sci. 2025; 25(24.

PMID: 39769431 PMC: 11727717. DOI: 10.3390/ijms252413669.

References

Chen K, Lou F, Yang F, Zhang J, Ye H, Chen W . Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Sci Rep. 2016; 6:31985. PMC: 4995492. DOI: 10.1038/srep31985. View

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

Rosenkranz S, Feldman J, McLaughlin V, Rischard F, Lange T, White R . Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021; 10(1):35-46. DOI: 10.1016/S2213-2600(21)00032-1. View

Arriagada R, Auperin A, Burdett S, Higgins J, Johnson D, Le Chevalier T . Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-77. PMC: 2853682. DOI: 10.1016/S0140-6736(10)60059-1. View

Park K, Haura E, Leighl N, Mitchell P, Shu C, Girard N . Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021; 39(30):3391-3402. PMC: 8791812. DOI: 10.1200/JCO.21.00662. View

Ptashkin R, Mandelker D, Coombs C, Bolton K, Yelskaya Z, Hyman D . Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncol. 2018; 4(11):1589-1593. PMC: 6224316. DOI: 10.1001/jamaoncol.2018.2297. View

Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts R . Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019; 5(10):1473-1478. PMC: 6681568. DOI: 10.1001/jamaoncol.2019.1838. View

Hui R, Ozguroglu M, Villegas A, Daniel D, Vicente D, Murakami S . Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(12):1670-1680. DOI: 10.1016/S1470-2045(19)30519-4. View

Hellmann M, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S, Carcereny Costa E . Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019; 381(21):2020-2031. DOI: 10.1056/NEJMoa1910231. View

10.

Abbosh C, Birkbak N, Swanton C . Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018; 15(9):577-586. DOI: 10.1038/s41571-018-0058-3. View

11.

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

12.

Yang Y, Zhang T, Wang J, Wang J, Xu Y, Zhao X . The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. Mol Cancer. 2022; 21(1):117. PMC: 9118575. DOI: 10.1186/s12943-022-01590-0. View

13.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

14.

Guo H, Li W, Wang B, Chen N, Qian L, Cui J . Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?. Chin J Cancer Res. 2021; 33(5):574-582. PMC: 8580798. DOI: 10.21147/j.issn.1000-9604.2021.05.04. View

15.

Parikh A, Van Seventer E, Siravegna G, Hartwig A, Jaimovich A, He Y . Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021; 27(20):5586-5594. PMC: 8530842. DOI: 10.1158/1078-0432.CCR-21-0410. View

16.

Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L . 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767. PMC: 8718623. DOI: 10.1182/blood.2021013626. View

17.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

18.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

19.

Deng J, Gao M, Gou Q, Xu C, Yan H, Yang M . Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors. Chin Med J (Engl). 2022; 135(12):1404-1413. PMC: 9481449. DOI: 10.1097/CM9.0000000000002217. View

20.

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View